Fintel reports that on January 7, 2026, Oppenheimer initiated coverage of Legend Biotech Corporation - Depositary Receipt (NasdaqGS:LEGN) with a Outperform recommendation.
Analyst Price Forecast Suggests 242.25% Upside
As of December 21, 2025, the average one-year price target for Legend Biotech Corporation - Depositary Receipt is $71.80/share. The forecasts range from a low of $48.48 to a high of $95.55. The average price target represents an increase of 242.25% from its latest reported closing price of $20.98 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Legend Biotech Corporation - Depositary Receipt is 798MM, a decrease of 12.17%. The projected annual non-GAAP EPS is -1.08.
What is the Fund Sentiment?
There are 378 funds or institutions reporting positions in Legend Biotech Corporation - Depositary Receipt. This is an decrease of 48 owner(s) or 11.27% in the last quarter. Average portfolio weight of all funds dedicated to LEGN is 0.32%, an increase of 13.75%. Total shares owned by institutions decreased in the last three months by 6.35% to 97,501K shares. 
The put/call ratio of LEGN is 0.62, indicating a bullish outlook.
What are Other Shareholders Doing?
Westfield Capital Management Co holds 6,094K shares. In its prior filing, the firm reported owning 6,473K shares , representing a decrease of 6.20%. The firm decreased its portfolio allocation in LEGN by 13.44% over the last quarter.
Hillhouse Capital Advisors holds 5,985K shares. No change in the last quarter.
FOCPX - Fidelity OTC Portfolio holds 4,684K shares. In its prior filing, the firm reported owning 1,174K shares , representing an increase of 74.93%. The firm increased its portfolio allocation in LEGN by 273.94% over the last quarter.
Suvretta Capital Management holds 3,818K shares. In its prior filing, the firm reported owning 3,774K shares , representing an increase of 1.15%. The firm decreased its portfolio allocation in LEGN by 21.07% over the last quarter.
FSPHX - Health Care Portfolio holds 3,452K shares. In its prior filing, the firm reported owning 2,800K shares , representing an increase of 18.88%. The firm increased its portfolio allocation in LEGN by 17.14% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
